Immutep refocuses Efti development after TACTI-004 review
Immutep (ASX:IMM) said it is narrowing future registration-directed development of eftilagimod alfa (efti) to head and neck squamous cell carcinoma (HNSCC) and soft tissue sarcoma (STS) following a review of its TACTI-004 study.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.